Navigation Links
Brain Scans Using New Dye May Predict Alzheimer's
Date:7/11/2012

WEDNESDAY, July 11 (HealthDay News) -- Brain scans using a new radioactive dye can detect early evidence of Alzheimer's disease in people who show little or no signs of the disease and may help predict future mental decline, a new study says.

It included 151 people who completed thinking and memory tests and underwent a PET (positron emission tomography) brain scan with the new dye called florbetapir (Amyvid). They were then followed for three years.

The dye binds to amyloid plaques that occur in the brains of people with Alzheimer's disease, enabling doctors to see if patients have the plaques and how much.

At the start of the study, 69 patients had normal mental function, 51 had mild impairment and 31 had Alzheimer's disease.

After 18 months, thinking and memory test results of patients who started off with mild impairment and whose brain scans revealed evidence of amyloid plaques worsened to a greater degree than those who had mild impairment but had no evidence of plaques at the start of the study.

The patients with amyloid plaques at the outset were also more likely to go on to develop Alzheimer's. After three years, 29 percent of the plaque-positive patients with mild impairment developed Alzheimer's compared with 10 percent of those with mild impairment who had no plaques at the start of the study.

Among participants with normal mental function at the start of the study, those with evidence of brain plaques showed more mental decline after 18 months than those with no sign of plaques.

"Even at a short follow-up of 18 months we can see how the presence of amyloid plaques affects cognitive [thinking] function," study co-leader Dr. P. Murali Doraiswamy, a professor of psychiatry at Duke University, said in a university news release. "Most people who come to the doctor with mild impairment really want to know the short-term prognosis and potential long-term effect."

There is no cure for Alzheimer's, but being able to detect the early stages of Alzheimer's could help advance efforts to find ways to fight the disease and enhance the care and treatment of current patients, he explained.

"For the most part we have been blind about who would progress and who wouldn't, so this approach is a step toward having a biomarker that predicts risk of decline in people who are experiencing cognitive impairment," Doraiswamy said.

The study, published online July 11 in the journal Neurology, was funded by Eli Lilly/Avid Radiopharmaceuticals, which markets Amyvid. Doraiswamy receives advisory and speaker fees from Lilly/Avid.

According to the U.S. Food and Drug Administration, Amyvid was approved in April for use in imaging tests for patients being evaluated for Alzheimer's.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about Alzheimer's disease.

-- Robert Preidt

SOURCE: Duke University, news release, July 11, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Epilepsy Leads to More Brain Abnormalities Over Time
3. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
4. Why is traumatic brain injury increasing among the elderly?
5. Brain Falters Near End of Life, but Games, Puzzles Might Slow Decline
6. Dental X-Rays May Be Linked to Benign Brain Tumors
7. Nonsurgical Method to Measure Brain Pressure Shows Promise
8. Researchers Map Brain Regions Linked to Intelligence
9. Football-related catastrophic brain injuries on the rise
10. Brain Tumor Vaccine Shows Promise in Early Trial
11. Brain Surgery Might Ease Tough-to-Treat OCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dermatology and women’s health, is pleased to announce the promotions of Allison Kelly ... sales team, Steve Catone to executive vice president of North American capital sales, ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... unparalleled clinical decision support technology, with highly adaptable algorithms, has been updated to ... patient has signs and symptoms consistent with Zikas and a travel history to ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... J.R. Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, corporate ... audits, privacy and security law, and best practices in data breaches for the ...
(Date:2/11/2016)... ... ... Colorado spine surgeon, Donald Corenman, MD, DC has been selected ... 2016 . The list consists of spine surgeons across the country nominated by their ... the importance of clinical excellence; he has been awarded the Patient’s Choice Award, Compassionate ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance ... involvement program, introduces a new charity campaign to raise funds for Ronald McDonald ... accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... BURLINGAME, Calif. , Feb. 11, 2016  NOIT™ ... announced a special "Gift of Change" campaign to assist ... units. For every such unit sold between February 10, ... a unit to a needy family. The NOIT is ... helping non/limited-verbal autistic individuals develop language skills. ...
(Date:2/11/2016)... Ore. , Feb. 11, 2016 Wellpartner, ... announce the acquisition of SolutionsRx, a full-service 340B company ... Along with providing traditional contract pharmacy services, SolutionsRx also ... clients in navigating the complex 340B regulatory environment. ... --> James R. Love , CEO of ...
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... M&A achieved through NPS and Dyax acquisitions and the announced ... with most robust pipeline in Shire , s ... most robust pipeline in Shire , s history ...
Breaking Medicine Technology: